ProQR Therapeutics (PRQR)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Rare Diseasesrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 46/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.45% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- ProQR Reports First Human Validation of RNA Editing Platform in Liver Disease
- ProQR Announces Appointment of Chris Hart as Chief Data and AI Officer and Thomas Wolf to join the Board of Directors as Strategic AI Advisor
- ProQR to Participate in Upcoming Investor Conferences in September 2026
- ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
- ProQR Announces Positive Phase 1 Target Engagement Data for AX-0810, Establishing First Clinical Validation of the Axiomer RNA Editing Platform
- ProQR Announces Annual General Meeting of Shareholders to be Held June 2, 2026
- ProQR Therapeutics N.V. (NASDAQ:PRQR) Analysts Just Slashed This Year's Revenue Estimates By 22%
- ProQR Announces First Quarter 2026 Operating and Financial Results
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Recent Publications
- From Phenotypic Screening to Target and Compound Prioritization for Autosomal Dominant Polycystic Kidney Disease. — SLAS Discov 2026 Sep 15 PMID 42744122
- Mice with humanized FXR ligand-binding domain display distinct metabolic responses upon pharmacological FXR stimulation. — J Lipid Res 2026 Aug PMID 42349717
- A First-in-Class mAb (BI-1607) Targeting FcγRIIB: Preclinical Data and First-in-Human Studies in Patients with HER2-Positive Advanced Solid Tumors. — Clin Cancer Res 2025 Dec 1 PMID 41071338
- Phase II INTEGRIS-PSC trial of bexotegrast, an α(v)β(6)/α(v)β(1) integrin inhibitor, in primary sclerosing cholangitis. — J Hepatol 2026 Jan PMID 41016442
- Addressing Challenges in Developing Treatments for Inherited Retinal Diseases: Recommendations From the Third Monaciano Symposium. — Transl Vis Sci Technol 2025 Aug 1 PMID 40862658
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for ProQR Therapeutics.
Full PRQR Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.